Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Core Viewpoint - Sol-Gel Technologies has entered into a product purchase agreement with Mayne Pharma for the sale and exclusive license of U.S. rights to EPSOLAY and TWYNEO, which will enhance the company's cash position and support the development of its product SGT-610 [1][6][7] Financial Summary - Sol-Gel will receive a total of $16 million from Mayne Pharma, with $10 million in Q2 2025 and $6 million in Q4 2025, extending the company's cash runway into Q1 2027 [1][9] - As of March 31, 2025, Sol-Gel had $16.9 million in cash and cash equivalents, with no marketable securities [5] Product Overview - EPSOLAY is a topical cream with 5% encapsulated benzoyl peroxide for treating inflammatory lesions of rosacea in adults [2][14] - TWYNEO is a fixed-dose combination cream containing 3% encapsulated benzoyl peroxide and 0.1% encapsulated tretinoin for treating acne vulgaris [2][13] Development Focus - The company will concentrate on the clinical and commercial development of SGT-610, a hedgehog signaling pathway blocker aimed at preventing basal cell carcinomas in Gorlin syndrome patients [3][15] - The U.S. market potential for SGT-610 is estimated to be between $400 million and $500 million annually [4][9] Clinical Trial Progress - The Phase-III clinical trial for SGT-610 is progressing well, with 80% of the planned patient enrollment completed, and top-line results expected in Q4 2026 [8][9] - The ongoing Phase 1b trial for SGT-210 in Darier disease patients has seen 50% of participants complete the trial [9][12] Market Potential - The global business potential for EPSOLAY and TWYNEO is expected to exceed that of the U.S. market, with many partnership agreements already signed [6][7] - SGT-210 has an estimated market potential of $200 million to $300 million if clinical efficacy is demonstrated [12]